F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

被引:0
|
作者
Marie-Bernadette Assié
Laurent Bardin
Agnès Auclair
Nathalie Consul-Denjean
François Sautel
Ronan Depoortère
Adrian Newman-Tancredi
机构
[1] Centre de Recherche Pierre Fabre,
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2007年 / 375卷
关键词
Antipsychotic; Mouse brain; F15063; Plasma levels; Apomorphine-induced climbing and sniffing; D2-like receptor occupancy;
D O I
暂无
中图分类号
学科分类号
摘要
F15063 (N-[(2,2-dimethyl-2,3-dihydro-benzofuran-7-yloxy)ethyl]-3-(cyclopent-1-enyl)-benzylamine fumarate salt) is a novel potential antipsychotic with dopamine D2/D3 blocking properties and agonist activity at 5-HT1A and D4 receptors. The pertinent parameter for pharmacological activity of antipsychotics appears to be central D2-like receptor occupancy. However, its duration is not necessarily correlated with drug plasma levels, on which clinical dosing regimens are often based. Thus, we compared in mice the duration of actions of F15063 and haloperidol to (1) inhibit apomorphine-induced climbing and sniffing (behavioural measures of D2-like receptor antagonism) and (2) occupy D2-like receptors in vivo in the striatum and olfactory tubercles (inhibition of [3H]nemonapride binding). Finally, we measured plasma levels of F15063. D2-like receptor occupancy in the striatum remained elevated at 1, 4 and 8 h postadministration, with both F15063 (ID50: 7.1, 3.6 and 16.5 mg/kg p.o., respectively) and the typical antipsychotic, haloperidol (ID50: 1.4, 0.52 and 0.53 mg/kg p.o., respectively). This was paralleled by a protracted inhibition of apomorphine-induced climbing (ED50: 0.9, 2.8 and 3.6 mg/kg p.o., and 0.21, 0.37 and 0.87 mg/kg p.o., respectively, for F15063 and haloperidol). In contrast, after administration of 10 mg/kg p.o. of F15063, its plasma levels decreased rapidly: 15.2, 2.1 and 0.6 ng/ml, 1, 4 and 8 h after administration, respectively. A similar pattern of results was observed when F15063 and haloperidol were administered i.p. and s.c., respectively. To summarise, the time-course of D2-like receptor occupancy and inhibition of apomorphine-climbing (and sniffing) behaviours was similarly long lasting with F15063 and haloperidol. In addition, the durations of action of F15063 and haloperidol in a behavioural model of antipsychotic-like activity were closely correlated to their occupancy of central D2-like receptors, and much longer than their presence in plasma.
引用
收藏
页码:241 / 250
页数:9
相关论文
共 16 条
  • [11] Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats
    V. Román
    I. Gyertyán
    K. Sághy
    B. Kiss
    Zs. Szombathelyi
    Psychopharmacology, 2013, 226 : 285 - 293
  • [12] Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15
    Kiss, Bela
    Laszlovszky, Istvan
    Horvath, Attila
    Nemethy, Zsolt
    Schmidt, Eva
    Bugovics, Gyula
    Fazekas, Karoly
    Gyertyan, Istvan
    Agai-Csongor, Eva
    Domany, Gyoergy
    Szombathelyi, Zsolt
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 378 (05) : 515 - 528
  • [13] Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15
    Béla Kiss
    István Laszlovszky
    Attila Horváth
    Zsolt Némethy
    Éva Schmidt
    Gyula Bugovics
    Károly Fazekas
    István Gyertyán
    Éva Ágai-Csongor
    György Domány
    Zsolt Szombathelyi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378 : 515 - 528
  • [14] Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
    Gyertyan, Istvan
    Saghy, Katalin
    Laszy, Judit
    Elekes, Ottilia
    Kedves, Rita
    Gemesi, Larisza I.
    Pasztor, Gabriella
    Zajer-Balazs, Maria
    Kapas, Margit
    Csongor, Eva Agai
    Domany, Gyoergy
    Kiss, Bela
    Szombathelyi, Zsolt
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 378 (05) : 529 - 539
  • [15] Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15
    István Gyertyán
    Katalin Sághy
    Judit Laszy
    Ottilia Elekes
    Rita Kedves
    Larisza I. Gémesi
    Gabriella Pásztor
    Mária Zájer-Balázs
    Margit Kapás
    Éva Ágai Csongor
    György Domány
    Béla Kiss
    Zsolt Szombathelyi
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 378 : 529 - 539
  • [16] Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dlhydro-1H-indol-3-yl)ethyl]-3, 6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: Characterisation of its in vitro profile and pre-clinical antipsychotic potential
    Hertel, Peter
    Didriksen, Michael
    Pouzet, Bruno
    BrennUrn, Lise T.
    Soby, Karina K.
    Larsen, Anna Kirstine
    Christoffersen, Claus T.
    Ramirez, Teresa
    Marcus, Monica M.
    Svensson, Torgny H.
    Di Matteo, Vincenzo
    Esposito, Ennio
    Bang-Andersen, Benny
    Arnt, Jorn
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 573 (1-3) : 148 - 160